NanoViricides, Inc. (OTC:NNVC) said on Monday that information about its novel proprietary anti-virus platform technology has been published in Bionanotechnology II: Global Prospects.
The book goes in-depth about its platform technology, evidence for how nanoviricides are believed to act plus results of nanoviricides specifically targeting viral diseases, such as HIV and the ocular disease, epidemic keratoconjunctivitis.
The book also discusses the role of nanotechnology in novel medical devices, bioanalytical technologies as well as nanobiomaterials.
Written by David Reisner, the book is a follow-up to his first volume. It contains 26 new contributions that provide a broad survey of research shaping this particular field.
CRC Press, the book’s publisher, said: “The impact and importance of nanotechnology continues to grow and nanomedicine and biotechnology have become areas of increased development.”
The company is developing drugs against a number of viral diseases including H1N1 swine flu, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Dengue fever, Hepatitis C, Rabies, and Ebola virus, among others.
Proactiveinvestors is a leading multi-media news organisation, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt and London.
No comments:
Post a Comment